Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
Purchase Benefits
What is included with this book?
José das Neves, Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto, Portugal
List of Contributors | p. xvii |
Foreword | p. xxiii |
Preface | p. xxv |
Acknowledgments | p. xxvii |
General Aspects of Chitosan | p. 1 |
Chemical and Technological Advances in Chitins and Chitosans Useful for the Formulation of Biopharmaceuticals | p. 3 |
Introduction | p. 3 |
Safety of Chitins and Chitosans | p. 4 |
Ionic Liquids: New Solvents and Reaction Media | p. 5 |
Chitin and Chitosan Nanofibrils | p. 8 |
Electrospun Nanofibers | p. 10 |
Polyelectrolyte Complexes and Mucoadhesion | p. 12 |
Conclusions and Future Perspectives | p. 16 |
Physical Properties of Chitosan and Derivatives in Sol and Gel States | p. 23 |
Introduction | p. 23 |
Chitin | p. 24 |
Chitosan | p. 28 |
Conclusions and Future Perspectives | p. 36 |
Absorption Promotion Properties of Chitosan and Derivatives | p. 45 |
Introduction | p. 45 |
Effect of Chitosan on the Intestinal Absorption of Poorly Absorbable Drugs | p. 47 |
Effect of Chitosan Derivatives on the Intestinal Absorption of Poorly Absorbable Drugs | p. 47 |
Effect of Chitosan Oligomers on the Intestinal Absorption of Poorly Absorbable Drugs | p. 48 |
Colon-Specific Delivery of Insulin Using Chitosan Capsules | p. 51 |
Conclusions and Future Perspectives | p. 54 |
Biocompatibility and Biodegradation of Chitosan and Derivatives | p. 57 |
Introduction | p. 57 |
Biocompatibility Evaluation of Chitosan and Derivatives | p. 58 |
Biodegradation of Chitosan and Derivatives | p. 65 |
Conclusions and Future Perspectives | p. 69 |
Biological and Pharmacological Activity of Chitosan and Derivatives | p. 75 |
Introduction | p. 75 |
Biological Activity | p. 76 |
Chitosan's Usefulness in Therapy and Alternative Medicine | p. 82 |
Conclusions and Future Perspectives | p. 84 |
Biological, Chemical, and Physical Compatibility of Chitosan and Biopharmaceuticals | p. 93 |
Introduction | p. 93 |
Structural Features of Chitosan and Its Derivatives | p. 94 |
Biocompatibility for Chitosan and Its Derivatives | p. 95 |
Biocompatibility of Photo-Cross-Linkable Chitosan Hydrogel | p. 98 |
Physical and Chemical Compatibility of Chitosan and Its Derivatives | p. 100 |
Conclusions and Future Perspectives | p. 102 |
Approaches for Functional Modification or Cross-Linking of Chitosan | p. 107 |
Introduction | p. 107 |
General Awareness of Chitosan Cross-Linking Methods | p. 108 |
Modified Chitosan: Synthesis and Characterization | p. 112 |
Applications of Modified Chitosan and Its Derivatives in Drug Delivery | p. 118 |
Conclusions and Future Perspectives | p. 118 |
Biopharmaceuticals Formulation and Delivery Aspects Using Chitosan and Derivatives | p. 125 |
Use of Chitosan and Derivatives in Conventional Biopharmaceutical Dosage Forms Formulation | p. 127 |
Introduction | p. 127 |
Advantageous Properties of Chitosan and Its Derivatives | p. 128 |
Oral Administration | p. 129 |
Buccal Administration | p. 131 |
Nasal Administration | p. 132 |
Pulmonary Administration | p. 132 |
Transdermal Administration | p. 133 |
Conclusions and Future Perspectives | p. 133 |
Manufacture Techniques of Chitosan-Based Microparticles and Nanoparticles for Biopharmaceuticals | p. 137 |
Introduction | p. 137 |
Water-in-Oil Emulsion and Chemical Cross-linking | p. 138 |
Drying Techniques | p. 141 |
Ionic Cross-linking Methods | p. 144 |
Coacervation and Precipitation Method | p. 151 |
Direct Interaction between Chitosan and Biopharmaceuticals | p. 152 |
Conclusions and Future Perspectives | p. 153 |
Chitosan and Derivatives for Biopharmaceutical Use: Mucoadhesive Properties | p. 159 |
Introduction | p. 159 |
Mucoadhesion | p. 160 |
Chitosan and Its Derivatives | p. 161 |
Biopharmaceutical Use of Chitosan and Its Derivatives | p. 171 |
Conclusions and Future Perspectives | p. 175 |
Chitosan-Based Systems for Mucosal Delivery of Biopharmaceuticals | p. 181 |
Introduction | p. 181 |
Important Challenges for the Delivery of Biopharmaceuticals by Mucosal Routes | p. 182 |
Interest in Chitosan for Mucosal Delivery of Biopharmaceuticals | p. 184 |
Chitosan-Based Delivery Nanosystems for Mucosal Delivery of Biopharmaceuticals | p. 188 |
Conclusions and Future Perspectives | p. 200 |
Chitosan-Based Delivery Systems for Mucosal Vaccination | p. 211 |
Introduction | p. 211 |
Adjuvant Properties of Chitosan | p. 212 |
Chitosan in the Delivery of Protein and Subunit Vaccines | p. 213 |
Chitosan-Based Formulations of DNAVaccines | p. 215 |
Vaccine Formulations Using Chitosan in Combination with Other Polymers | p. 216 |
Chitosan Derivatives in Vaccine Carrier Design | p. 217 |
Conclusions and Future Perspectives | p. 220 |
Chitosan-Based Nanoparticulates for Oral Delivery of Biopharmaceuticals | p. 225 |
Introduction | p. 225 |
Challenges on the Oral Delivery of Therapeutic Proteins | p. 226 |
Challenges on the Oral Delivery of Genetic Material | p. 227 |
Role of Chitosan in the Protection of Biopharmaceuticals in the Gastrointestinal Tract | p. 229 |
Chitosan-Based Nanoparticles for Oral Delivery of Therapeutic Proteins | p. 232 |
Chitosan-Based Nanoparticles for Oral Delivery of Genetic Material | p. 234 |
Conclusions and Future Perspectives | p. 236 |
Chitosan-Based Systems for Ocular Delivery of Biopharmaceuticals | p. 243 |
Introduction | p. 243 |
Ocular Delivery of Biopharmaceuticals | p. 244 |
Chitosan: A Suitable Biomaterial for Ocular Therapeutics | p. 244 |
Chitosan-Based Systems for Ocular Delivery of Biomacromolecules | p. 245 |
Toxicological and Compatibility Aspects of Chitosan-Based Ocular Systems | p. 249 |
Conclusions and Future Perspectives | p. 250 |
Chemical Modification of Chitosan for Delivery of DNA and siRNA5 | p. 25 |
Introduction | p. 255 |
Hydrophilic Modification | p. 256 |
Hydrophobic Modification | p. 257 |
Specific Ligand Modification | p. 259 |
pH-Sensitive Modification | p. 264 |
Conclusions and Future Perspectives | p. 269 |
Advanced Application of Chitosan and Derivatives for Biopharmaceuticals | p. 275 |
Target-Specific Chitosan-Based Nanoparticle Systems for Nucleic Acid Delivery | p. 277 |
Introduction | p. 277 |
Chitosan-Based Nanoparticle Delivery Systems | p. 283 |
Illustrative Examples of DNAVaccine Delivery | p. 286 |
Illustrative Examples of Nucleic Acid Delivery Systems for Cancer Therapy | p. 288 |
Illustrative Examples of Nucleic Acid Delivery Systems for Anti-Inflammatory Therapy | p. 291 |
Conclusions and Future Perspectives | p. 294 |
Functional PEGylated Chitosan Systems for Biopharmaceuticals | p. 301 |
Introduction | p. 301 |
PEGylated Chitosan for the Delivery of Proteins and Peptides | p. 304 |
PEGylated Chitosan for Delivery of Nucleic Acids | p. 308 |
PEGylated Chitosan for Delivery of Other Macromolecular Biopharmaceuticals | p. 311 |
PEGylated Chitosan Used for Cellular Scaffolds | p. 313 |
Conclusions and Future Perspectives | p. 313 |
Stimuli-Sensitive Chitosan-Based Systems for Biopharmaceuticals | p. 319 |
Introduction | p. 319 |
pH-Sensitive Chitosan-Based Systems | p. 319 |
Thermosensitive Chitosan-Based Systems | p. 321 |
pH-Sensitive and Thermosensitive Chitosan-Based Systems | p. 323 |
pH- and Ionic-Sensitive Chitosan-Based Systems | p. 325 |
Photo-Sensitive Chitosan-Based Systems | p. 325 |
Electrical-Sensitive Chitosan-Based Systems | p. 326 |
Magnetic-Sensitive Chitosan-Based Systems | p. 326 |
Chemical Substance-Sensitive Chitosan-Based Systems | p. 327 |
Conclusions and Future Perspectives | p. 327 |
Chitosan Copolymers for Biopharmaceuticals | p. 333 |
Introduction | p. 333 |
Chitosan-g-Poly(Ethylene Glycol) | p. 337 |
Chitosan-g-Polyethylenimine | p. 347 |
Other Copolymers of Chitosan | p. 357 |
Copolymers of Chitosan with Promising Applications | p. 363 |
Conclusions and Future Perspectives | p. 368 |
Application of Chitosan for Anticancer Biopharmaceutical Delivery | p. 381 |
Introduction | p. 381 |
Chitosan and Cancer: Intrinsic Antitumor Activity of the Polymer Itself | p. 382 |
Chitosan Formulations Developed for Classic Anticancer Drugs | p. 383 |
Biopharmaceuticals Delivered by Chitosan Preparations | p. 384 |
Active Targeting Strategies and Multifunctional Chitosan Formulations | p. 388 |
Conclusions and Future Perspectives | p. 389 |
Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine | p. 393 |
Introduction | p. 393 |
Fabrication of Chitosan-Based Biopharmaceuticals Scaffolds | p. 395 |
Applications of Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine | p. 403 |
Future Trends: Regenerative Engineering | p. 416 |
Conclusions and Future Perspectives | p. 417 |
Wound-Healing Properties of Chitosan and Its Use in Wound Dressing Biopharmaceuticals | p. 429 |
Introduction | p. 429 |
Brief Review of Wound Repair | p. 430 |
Wound-Healing Effects of Chitosan | p. 433 |
Chitosan for Wound Therapeutics Delivery | p. 440 |
Conclusions and Future Perspectives | p. 444 |
Regulatory Status, Toxicological Issues, and Clinical Perspectives | p. 451 |
Toxicological Properties of Chitosan and Derivatives for Biopharmaceutical Applications | p. 453 |
Introduction | p. 453 |
In Vitro Toxicity of Chitosan and Derivatives | p. 454 |
In Vivo Toxicity of Chitosan and Derivatives | p. 457 |
Conclusions and Future Perspectives | p. 459 |
Regulatory Status of Chitosan and Derivatives | p. 463 |
Introduction | p. 463 |
Source | p. 464 |
Characterization | p. 464 |
Purity | p. 465 |
Applications of Advanced Uses of Chitosan | p. 466 |
Regulatory Considerations for Chitosan and Chitosan Derivatives in the European Union, and Medical Devices or Combination Products with Medical Device (CDRH) Lead | p. 468 |
Regulatory Pathways | p. 469 |
Chitosan Medical Products: US Regulatory Review Processes for Medical Devices or Combination Products with CDRH Lead | p. 469 |
Chitosan Wound Dressings | p. 470 |
The European Regulatory System: The European Medicines Agency (EMA) and European Directorate for the Quality of Medicines (EDQM) | p. 474 |
Further Regulatory Considerations | p. 475 |
Conclusions and Future Perspectives | p. 477 |
Disclaimer | p. 478 |
Patentability and Intellectual Property Issues Related to Chitosan-Based Biopharmaceutical Products | p. 483 |
Introduction | p. 483 |
Setting the Scene: The Role of Chitosan as a Pharmaceutical Excipient | p. 484 |
Addressing the Drivers for Scientific Progress on Chitosan: Innovation and Inventability | p. 495 |
Conclusions and Future Perspectives | p. 496 |
Quality Control and Good Manufacturing Practice (GMP) for Chitosan-Based Biopharmaceutical Products | p. 503 |
Introduction | p. 504 |
Regulatory Requirements for Production | p. 505 |
Manufacturing GMP: Fundamental Considerations | p. 508 |
Requirements for Rooms, Personnel, and Equipment | p. 511 |
Qualification and Validation | p. 511 |
Quality Control | p. 513 |
Monitoring and Maintenance of a GMP System | p. 519 |
Conclusions and Future Perspectives | p. 522 |
Preclinical and Clinical Use of Chitosan and Derivatives for Biopharmaceuticals: From Preclinical Research to the Bedside | p. 525 |
Introduction | p. 525 |
Chitosan as a Parenteral (Subcutaneous) Vaccine Platform | p. 526 |
Chitosan as an Immunotherapeutic Platform | p. 530 |
Conclusions and Future Perspectives | p. 537 |
References | p. 539 |
Index | p. 543 |
Table of Contents provided by Publisher. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.